{"entity":{"id":"nct07541079","kind":"trial","name":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)","aka":[],"tldr":"A phase 3 trial of Giredestrant in advanced solid tumours, run by Genentech, Inc., now recruiting.","summary":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) is a phase 3 interventional study registered as NCT07541079 by Genentech, Inc., with 300 participants planned, started 2026-08-25 and due to reach its primary completion in 2032-06-30. Interventions recorded: Giredestrant.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07541079","url":"https://clinicaltrials.gov/study/NCT07541079"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":["giredestrant"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07541079","phase":"3","setting":"A Phase IIIb, Single-Arm, Open-Label Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes (PRO) of Giredestrant in Patients With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy","sponsor":"Genentech, Inc.","participation":[{"nct":"NCT07541079","source":"https://clinicaltrials.gov/study/NCT07541079","fetchedAt":"2026-10-07T16:55:48.292Z","studySha256":"d93382e97e8feb383f332d94c22d4f0448aa1f50d7a24c678c1a588f3b9b5aef","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-14","leadSponsor":"Genentech, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":300,"enrolmentType":"ESTIMATED","siteCount":2,"recruitingSiteCount":2,"countries":["United States"]}],"started":"2026-08-25","startedType":"actual","enrolled":300,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07541079/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"drug":[{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}